Predicting relapses in MOGAD

MOGCast Memory: Predicting RelapseПодробнее

The MOG Project Q&A Roundtable Discussion on Hot Topics in MOGAD with the ExpertsПодробнее

METEOROID: Phase III trial of satralizumab in patients with MOGADПодробнее

Management: Predicting RelapseПодробнее

2021 RNDS | Anti-MOG Associated Disorder: Insights Into Neuroplasticity and Opportunities for RepairПодробнее

Assessing predictors of relapse in MOGAD patientsПодробнее

2022 Pre-RNDS | MOG Antibody Disease (MOGAD)Подробнее

Predictive and prognostic biomarkers for pediatric MOGAD and NMOSDПодробнее

cosMOG: anti-FcRn agent rozanolixizumab for relapse prevention in MOGADПодробнее

2021 RNDS | Living with ADEM, AFM, MOGAD, NMOSD, ON and TMПодробнее

The More You Know: Relapse or Pseudo RelapseПодробнее

205. MOGAD and NMOSD: Is MOGAD Part of NMOSD or a Distinct Diagnosis?Подробнее

Research developments in MOGADПодробнее

Predictors of conversion from positive to negative MOG antibody statusПодробнее

Overlaps & Differences Between MOGAD, MS & NMOSDПодробнее

Treatment Options for MOGADПодробнее

Cognitive & Behavioral: Symptoms of RelapseПодробнее

2024 MOGAD Together | Community Q&AПодробнее

2022 RNDS | How do I know if I am having a relapse?Подробнее

2022 RNDS | Learn about new clinical trials in MOGADПодробнее